Prot #BO29337: A Phase II, Open-Label Study Evaluating the Safety and Efficacy of GDC-0199 (ABT-199) Plus Bendamustine Plus Rituximab (BR) in Comparison with BR Alone or GDC-0199 Plus Rituximab (R) in Patients with Relapsed and Refractory Follicular Non-H

Project: Research project

StatusActive
Effective start/end date4/10/154/30/20

Funding

  • Covance Inc. (Prot #BO29337)
  • Genentech, Inc. (Prot #BO29337)